Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS Negl Trop Dis ; 13(8): e0007115, 2019 08.
Article in English | MEDLINE | ID: mdl-31398203

ABSTRACT

BACKGROUND: Ghana started its national programme to eliminate lymphatic filariasis (LF) in 2000, with mass drug administration (MDA) with ivermectin and albendazole as main strategy. We review the progress towards elimination that was made by 2016 for all endemic districts of Ghana and analyze microfilaria (mf) prevalence from sentinel and spot-check sites in endemic districts. METHODS: We reviewed district level data on the history of MDA and outcomes of transmission assessment surveys (TAS). We further collated and analyzed mf prevalence data from sentinel and spot-check sites. RESULTS: MDA was initiated in 2001-2006 in all 98 endemic districts; by the end of 2016, 81 had stopped MDA after passing TAS and after an average of 11 rounds of treatment (range 8-14 rounds). The median reported coverage for the communities was 77-80%. Mf prevalence survey data were available for 430 communities from 78/98 endemic districts. Baseline mf prevalence data were available for 53 communities, with an average mf prevalence of 8.7% (0-45.7%). Repeated measurements were available for 78 communities, showing a steep decrease in mean mf prevalence in the first few years of MDA, followed by a gradual further decline. In the 2013 and 2014 surveys, 7 and 10 communities respectively were identified with mf prevalence still above 1% (maximum 5.6%). Fifteen of the communities above threshold are all within districts where MDA was still ongoing by 2016. CONCLUSIONS: The MDA programme of the Ghana Health Services has reduced mf prevalence in sentinel sites below the 1% threshold in 81/98 endemic districts in Ghana, yet 15 communities within 13 districts (MDA ongoing by 2016) had higher prevalence than this threshold during the surveys in 2013 and 2014. These districts may need to intensify interventions to achieve the WHO 2020 target.


Subject(s)
Disease Eradication/methods , Elephantiasis, Filarial/drug therapy , Elephantiasis, Filarial/epidemiology , Albendazole/therapeutic use , Animals , Child , Child, Preschool , Elephantiasis, Filarial/diagnosis , Elephantiasis, Filarial/prevention & control , Endemic Diseases , Female , Ghana/epidemiology , Health Services Research , Humans , Ivermectin/therapeutic use , Male , Mass Drug Administration/methods , Microfilariae/pathogenicity , Prevalence , Surveys and Questionnaires , World Health Organization
3.
Trans R Soc Trop Med Hyg ; 110(12): 690-695, 2016 12 01.
Article in English | MEDLINE | ID: mdl-28938053

ABSTRACT

Background: Among the 216 districts in Ghana, 98 were declared endemic for lymphatic filariasis in 1999 after mapping. Pursuing the goal of elimination, WHO recommends annual treatment using mass drugs administration (MDA) for at least 5 years. MDA was started in the country in 2001 and reached national coverage in 2006. By 2014, 69 districts had 'stopped-MDA' (after passing the transmission assessment survey) while 29 others remained with persistent microfilaraemia (mf) prevalence (≥1%) despite more than 11 years of MDA and were classified as 'hotspots'. Methods: An ecological study was carried out to compare baseline mf prevalence and anti-microfilaria interventions between hotspot and stopped-MDA districts. Results: Baseline mf prevalence was significantly higher in hotspots than stopped-MDA districts (p<0.001). After three years of MDA, there was a significant decrease in mf prevalence in hotspot districts, but it was still higher than in stopped-MDA districts. The number of MDA rounds was slightly higher in hotspot districts (p<0.001), but there were no differences in coverage of MDA or long-lasting-insecticide-treated nets. Conclusions: The main difference in hotspots and stopped-MDA districts was a high baseline mf prevalence. This finding indicates that the recommended 5-6 rounds annual treatment may not achieve interruption of transmission.


Subject(s)
Elephantiasis, Filarial/drug therapy , Elephantiasis, Filarial/epidemiology , Endemic Diseases/prevention & control , Endemic Diseases/statistics & numerical data , Filaricides/administration & dosage , Mass Drug Administration/statistics & numerical data , Animals , Antigens, Helminth/immunology , Disease Transmission, Infectious/prevention & control , Drug Administration Schedule , Elephantiasis, Filarial/prevention & control , Elephantiasis, Filarial/transmission , Filaricides/pharmacology , Filaricides/therapeutic use , Ghana/epidemiology , Health Services Research , Humans , Microfilariae/immunology , Prevalence , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...